Blog

Our blog provides updates on Absolute Antibody’s technologies, products and services. Browse the latest posts to learn about company developments and events.

Supporting Neurobiology Research with Neural Marker Antibodies

Engineered Antibodies for Neurodegenerative Disease Research

Antibody Humanization to Combat Antimicrobial Resistant Bacteria

Is Fc Silencing Right for Your Antibody?

From Micrograms to Many, Antibody Protein Sequencing to Maintain Anti-CD42a Clone ESS

How to Choose an Antibody CRO

An Introduction to Recombinant Antibody Technology for Diagnostic Applications

Improve your Flow Cytometry with FIX&PERM® Buffers and Recombinant Engineered Antibodies

Anti-CD47 Antibodies: A Promising Approach for Cancer Immunotherapy

PD-L1 and PD-L2: PD-1 Ligands in Cancer Immunotherapy

Applying Recombinant Antibody Engineering to Further Immunoassay Development

Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More

VivopureX™ Microgrant Winners Announced

A Question of Isotype: How Switching Antibody Isotypes and Fc Regions Promotes Discovery

Advancing Cancer Immunotherapy: A Closer Look at Anti-VISTA Antibodies

9 Questions to Consider Before Your Next Antibody Engineering Project

Selecting the Right Cell Line to Empower Your Cancer Antibody Research

Collaborating on an Antibody Match Pair for COVID-19 Research

Supporting Cancer Immunotherapy Research: Recombinant, Syngeneic Antibodies Against Mouse PD-1

An Introduction to Absolute Antibody Custom Services

Submit Your VivopureX™ Research Proposal to Earn a Research Microgrant from Absolute Antibody

Science Showcase: All About the Antibodies

Engineering Antibody Reagents to Facilitate In Vivo Research

Comparing potential bispecific formats of trastuzumab and a humanized OKT3

Converting a Popular Puromycin Antibody to Recombinant Production

Antibody Humanization for Infectious Disease Serological Assay Development

Supporting Alzheimer’s Research: Recombinant Antibodies Against Amyloid Beta

PEGS Europe – Booth #1310

5-7th November 2024

Barcelona, Spain

Recombinant Antibodies Against Influenza A Virus Subtype H5N1

Engineered Mouse-Ly-6G Antibody Shows Near Complete Neutrophil Depletion In Vivo